Delving into the Latest Updates on Terconazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Terconazole (USP/INN), Fungistat

+ [3]

Target-

Mechanism

fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors)

Therapeutic Areas

Infectious DiseasesUrogenital Diseases

Active Indication

Candidiasis, Vulvovaginal

Inactive Indication-

Originator Organization

Johnson & Johnson

Active Organization

Shanghai Shyndec Pharmaceutical Co., Ltd.

Fougera Pharmaceuticals, Inc.Taro Pharmaceuticals U.S.A., Inc.

Inactive Organization

Curatek Pharmaceuticals, LLC

Janssen Pharmaceuticals, Inc.Janssen-Cilag SA

Drug Highest PhaseApproved

First Approval Date

US (31 Dec 1987),

Candidiasis, Vulvovaginal

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC26H31Cl2N5O3

InChIKeyBLSQLHNBWJLIBQ-OZXSUGGESA-N

CAS Registry67915-31-5

A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)

The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).

Start Date01 Dec 2007

Sponsor / Collaborator

Janssen-Cilag SA

100 Clinical Results associated with Terconazole

Login to view more data

100 Translational Medicine associated with Terconazole

Login to view more data

100 Patents (Medical) associated with Terconazole

Login to view more data

115

Literatures (Medical) associated with Terconazole

26 Sep 2023·ACS omega

Expired Antifungal Drugs as Effective Corrosion Inhibitors for Carbon Steel in 1 M HCl Solution: Practical and Theoretical Approaches.

Article

Author: Motawea, Mohamed S ; Abdallah, Metwally ; Al-Bonayan, Ameena Mohsen ; Soliman, Kamal A ; Alfakeer, Majda ; Al-Juaid, Salih S ; Hawsawi, Hanaa ; Abd El Wanees, Salah

The anticorrosion potency of two expired antifungal drugs, namely, bifonazole (BIF) and terconazole (TER), for X65 carbon steel (X65CS) in a 1.0 M HCl solution was estimated using practical and computational measurements. The results of all methods applied showed that the percentage of anticorrosive efficacy (% AE) increased for expired BIF and TER and reduced at elevated temperatures. The % AE values of expired BIF and TER (375 mg L^-1) reached 92.08 and 94.19%, respectively, using polarization methods. The anticorrosion activities of the two expired drugs were interpreted based on their adsorption on the X65CS surface. The adsorption occurred according to the Langmuir isotherm model. The polarization results indicated that the expired drugs BIF and TER were mixed inhibitors. The impedance results showed a single capacitive loop, confirming that the charge transfer process controlled the corrosion of X65CS. Expired BIF and TER served as good pitting inhibitors by shifting the pitting potential to positive values. The thermodynamic functions of activation and adsorption were defined and explained. Density functional theory and Monte Carlo simulations were used to investigate the BIF and TER inhibitors. The theoretical parameters were consistent with the experimental results. The anticorrosion efficiencies determined using the various methods were in complete agreement.

31 Dec 2022·Drug Delivery

PLGA-modified Syloid^®-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

Article

Author: Elkasabgy, Nermeen A. ; Zaghloul, Nada ; El Hoffy, Nada M. ; Mahmoud, Azza A.

The eye is an invulnerable organ with intrinsic anatomical and physiological barriers, hindering the development of a pioneer ocular formulation. The aim of this work was to develop an efficient ocular delivery system that can augment the ocular bioavailability of the antifungal drug, terconazole. Mesoporous silica microparticles, Syloid^® 244 FP were utilized as the carrier system for terconazole. Preliminary studies were carried out using different drug:Syloid^® weight ratios. The optimum weight ratio was mixed with various concentrations (30 and 60%w/w) of poly (lactic-co-glycolic acid) (PLGA), ester or acid-capped and with different monomers-ratio (50:50 and 75:25) using the nano-spray dryer. Results revealed the superiority of drug:Syloid^® weight ratio of 1:2 in terms of yield percentage (Y%), SPAN and drug content percentage (DC%). Furthermore, incorporation of PLGA with lower glycolic acid monomer-ratio significantly increased Y%. In contrast, increasing the glycolic acid monomer-ratio resulted in higher DC% and release efficiency percentage (RE%). Additionally, doubling PLGA concentration significantly reduced Y%, DC%, drug loading percentage (DL%) and RE%. Applying desirability function in terms of increasing DC%, DL% besides RE% and decreasing SPAN, the selected formulation was chosen for DSC, XRD and SEM investigations. Results confirmed the successful loading of amorphized terconazole on PLGA-modified Syloid^® microparticles. Moreover, pharmacokinetic studies for the chosen formulation on male Albino rabbits' eyes revealed a 2, 6.7 and 25.3-fold increase in mean residence time, C_max and AUC_0-24-values, respectively, compared to the drug suspension. PLGA-modified Syloid^® microparticles represent a potential option to augment the bioavailability of ocular drugs.

01 Jul 2022·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

Development of the stability-indicating method, structural elucidation of new photodegradation products from terconazole by LC-MS TOF, and in vitro toxicity

Q3 · MEDICINE

Article

Author: Ribeiro, José Izak ; Leal, Leila Bastos ; de Souza, Larissa Xavier ; Sobrinho, José Lamartine Soares ; Bedor, Danilo César Galindo ; de Castro, Whocely Victor ; Santana, Davi Pereira de ; da Silva Aquino, Kátia Aparecida ; Kishishita, Juliana ; da Silva, José Wellithom Viturino

Terconazole (TCZ) was the first triazole antifungal drug launched in the market and has been used in the treatment of vulvovaginal candidiasis. It is also indicated to treat dermatophytosis and fungal ocular infections. However, some of the degradation products from triazole drugs have been reported to be toxic, justifying the need of further investigations about the stability of TCZ. identification of its degradation products and evaluation of their toxicity considering the new possibilities of therapeutic indications. Therefore, in this work a systematic investigation regarding photostability of TCZ was conducted. The active pharmaceutical ingredient (API) and its methanolic solution (100 µg mL^-1) were kept into a photostability chamber under a UV light (200 Wh/m²; 1.2 × 10⁶ lux/h) during 5 days and 90 min, respectively. A high-efficiency liquid chromatography method was developed for separation and identification of TCZ and its degradation products. The solid-state API remained stable throughout the test, whereas an extensive degradation was observed when in solution. In this case, four degradation products not yet reported in the literature were identified and characterized by electrospray ionization high-resolution quadrupole time-of-flight mass spectrometry (ESI-QTOF-MS). Two degradation products presented m/z of 498 and the other two of 496 and 464, respectively. The results suggest that the degradation follows a first-order kinetic and involves the loss of chlorine atoms from the 2,4-dichlrophenyl moiety. Finally, TCZ submitted to the same stress condition as the API solution, increased significantly the opacity during the bovine corneal opacity and permeability test method (BCOP) indicating a potential to cause ocular toxicity. Further studies using the pure photolysis degradation products of TCZ characterized in this work are still necessary to confirm this find.

1

News (Medical) associated with Terconazole

22 Mar 2006

·www.biospace.com

Perrigo Company Announces Approval For Terconazole Suppositories

ALLEGAN, Mich., March 21 /PRNewswire-FirstCall/ -- The Perrigo Company announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market terconazole vaginal suppositories, 80 mg. The product is the AB-rated equivalent to Ortho-McNeil Pharmaceutical's Terazol(R) 3 Vaginal Suppositories, 80 mg, an anti-fungal medication indicated for the treatment of vaginal candida (yeast) infections. Perrigo is currently the only approved generic for this product. Shipments will begin immediately. According to NDC data, annual U.S. sales are approximately $8.5 million. The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico and Germany. Visit Perrigo on the Internet ( ). Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. Please see the "Cautionary Note Regarding Forward-Looking Statements" on pages 33 - 41 of the Company's Form 10-K for the year ended June 25, 2005, as well as the Company's subsequent filings with the Securities and Exchange Commission, for a discussion of certain important factors that relate to forward-looking statements contained in this press release. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Perrigo Company CONTACT: Ernest J. Schenk, Manager, Investor Relations and Communicationof Perrigo Company, +1-269-673-9212, E-mail: eschenk@perrigo.com Web site:

Generic Drug

100 Deals associated with Terconazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00888	Terconazole	G01AG02	DB00251

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Vulvovaginal	US	Taro Pharmaceuticals U.S.A., Inc.	06 Apr 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Vaginal Diseases	Preclinical	US	Curatek Pharmaceuticals, LLC	01 Jun 2015
Vaginitis	Preclinical	MX	Janssen-Cilag SA	01 Dec 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02308007 (CTgov)	Phase 3	Infective vaginitis \| Infectious Diseases	475	Terconazole (Terconazole Vaginal Gel)	faylzrdjul(aoshgpzojh) = moahosmgvc pekccaoqkb (jbpkgytrtk, qktxpzjhvy - vjhvchzoxm) View more	-	04 Aug 2020
				Metronidazole (Metronidazole Vaginal Gel)	faylzrdjul(aoshgpzojh) = nowuipnequ pekccaoqkb (jbpkgytrtk, xagthvghkz - wwtybqcmyr) View more
NCT02308046 (CTgov)	Phase 3	Infective vaginitis \| Infectious Diseases	212	Terconazole (Terconazole Vaginal Gel)	(nujoksntmx) = egmqtvwzlj kpelahfgrm (pkbrrzkufe, jckoswnwyg - mnqslqsfki) View more	-	27 Jul 2020
				Placebo (Gel Vehicle)	(nujoksntmx) = lgucseuzkx kpelahfgrm (pkbrrzkufe, phvrnizaph - nrtrfxesrc) View more
NCT02180100 (Pubmed)	Phase 4	Candidiasis, Vulvovaginal	140	Terconazole vaginal suppository	(ewkankgxna) = flyzkfidss zephiipntz (rybiodmtgp ) View more	Positive	01 Jun 2015
				Oral fluconazole	(ewkankgxna) = vcajsujaim zephiipntz (rybiodmtgp ) View more
NCT01867164 (CTgov)	Phase 3	Vaginitis	160	Terconazole+Fluocinolone Acetonide+Clindamycin (Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide))	(dcsdkweqti) = tswjcxxwux ubdeqiwble (pjwravuwmb, nvmczsbfpw - okdgcsfloj) View more	-	24 Dec 2013
				Fluocinolone Acetonide+Nystatin+Metronidazole (Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin))	(dcsdkweqti) = jwtgvznaum ubdeqiwble (pjwravuwmb, tdbwcabvhy - nunfsfymcr) View more
NCT00803738 (CTgov)	Not Applicable	Candidiasis, Vulvovaginal	572	Terconazole (Terconazole Vaginal Suppositories, 80 mg - Perrigo)	qnjqgzmjin(ekvtdbhpmi) = frtmnuctmz mpegwmjfyw (cwlrwlyody, rzdtfvognj - hzhpdossca) View more	-	20 Feb 2013
				Terazol 3 - Terconazole (Terazol 3 - Terconazole Vaginal Suppositories 80 mg)	qnjqgzmjin(ekvtdbhpmi) = mfqflknsko mpegwmjfyw (cwlrwlyody, kfkcxbvvzr - mvpwnvxjcj) View more